You are here: Industry Insights > METex14

News List

FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations prnasia
February 04, 2021
Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has approved TEPMETKO® (tepotinib) following Priority Review for the treatment of adult patients with metastatic non-small cell lung cancer ...
FDA Accepts NDA Filing for Tepotinib for Metastatic NSCLC with METex14 Skipping Alterations americanpharmaceuticalreview
August 26, 2020
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, has announced the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the new drug application (NDA) for ...
Novartis gets FDA nod for Tabrecta to treat metastatic NSCLC with METex14 pharmaceutical-business-review
May 11, 2020
Novartis has secured approval from the US Food and Drug Administration (FDA) for its Tabrecta (capmatinib) to treat adult patients metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14).
Speedy US approval for Novartis' Tabrecta pharmatimes
May 07, 2020
Novartis' Tabrecta (capmatinib, formerly INC280) has been awarded accelerated approval by the US Food and Drug Administration for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that leads to MET ex